48660 
Federal Register / Vol. 52, No. 246 / Wednesday, December 23. 1987 / Notices 
DEPARTMENT OF HEALTH AND 
HUMAN SERVICES 
National Institutes of Health 
Recombinant DNA Advisory 
Committee; Meeting 
Pursuant to Pub. L. 92^163, notice is 
hereby given of a meeting of the 
Recombinant DNA Advisory Committee 
at the National Institutes of Health, 
Building 31C, Conference Room 10, 9000 
Rockville Pike, Bethesda, Maryland 
20892, on February 1, 1988, from 
approximately 9 a.m. to adjournment at 
approximately 5 p.m. This meeting will 
be open to the public to discuss: 
Amendment of Guidelines, 
Proposed major action. 
Other matters to be considered by the 
Committee. 
Attendance by the public will be 
limited to space available. Members of 
the public wishing to speak at the 
meeting may be given such an 
opportunity at the discretion of the 
Chair. 
Dr. William J. Gartland, Executive 
Secretary, Recombinant DNA Advisory 
Committee, National Institutes of 
Health. 12441 Parklawn Drive, Suite 58, 
Rockville, Maryland 20852, telephone 
(301) 770-0131, will provide materials to 
be discussed at the meeting, rosters of 
committee members, and substantive 
program information. A summary of the 
meeting will be available at a later date. 
OMB’s "Mandatory Information 
Requirements for Federal Assistance Program 
Announcements" (45 FR 39592) requires a 
statement concerning the official government 
programs contained in the Catalog of Federal 
Domestic Assistance. Normally NIH lists in 
its announcements the number and title of 
affected individual programs for the guidance 
of the public. Because the guidance in this 
notice covers not only virtually every NIH 
program but also essentially every Federal 
research program in which DNA recombinant 
molecule techniques could be used, it has 
been determined to be not cost effective or in 
the public interest to attempt to list these 
programs. Such a list would likely require 
several additional pages. In addition, NIH 
could not be certain that every Federal 
program would be included as many Federal 
agencies, as well as private organizations, 
both national and international, have elected 
to follow the NIH Guidelines. In lieu of the 
individual program listing, NIH invites 
readers to direct questions to the information 
address above about whether individual 
programs listed in the Catalog of Federal 
Domestic Assistance are affected. 
Dated: December 14, 1987. 
Betty J. Beveridge, 
Committee Management Officer, National 
Institutes of Health. 
(FR Doc. 87-29465 Filed 12-22-87; 8:45 am] 
BILLING COOE 4140-01-41 
Recombinant DNA Research; 
Proposed Action Under Guidelines 
agency: National Institutes of Health, 
PHS, DHHS. 
ACTION: Notice of proposed action under 
NIH Guidelines for Research Involving 
Recombinant DNA Molecules. 
summary: This notice sets forth a 
proposed action to be taken under the 
National Institutes of Health (NIH) 
Guidelines for Research Involving 
Recombinant DNA Molecules. 
Interested parties are invited to submit 
comments concerning this proposal. This 
proposal will be considered by the 
Recombinant DNA Advisory Committee 
(RAC] at its meeting on February 1, 
1988. After consideration of this 
proposal and comments by the RAC, the 
Director of the National Institutes of 
Health will issue a decision on this 
proposal in accord with the NIH 
Guidelines. 
DATES: Comments received by January 
19, 1988, will be reproduced and 
distributed to the RAC for consideration 
at its February 1, 1988, meeting. 
ADDRESS: Written comments and 
recommendations should be submitted 
to the Director, Office of Recombinant 
DNA Activities, 12441 Parklawn Drive, 
Room 58, Rockville, MD 20852. All 
comments received in timely response to 
this notice will be considered and will 
be available for public inspection in the 
above office on weekdays between the 
hours of 8:30 a.m. and 5:00 p.m. 
FOR FURTHER INFORMATION CONTACT: 
Background documentation and 
additional information can be obtained 
from the Office of Recombinant DNA 
Activities, 12441 Parklawn Drive, Room 
58. Rockville. Maryland 20852. (301) 770- 
0131. 
SUPPLEMENTARY INFORMATION: The NIH 
will consider the following action under 
the NIH Guidelines for Research 
Involving Recombinant DNA Molecules: 
Large-Scale Production Involving 
Cephalosporium Acremonium Strain 
LLJ 4-79-6 
In a letter dated December 4, 1987, Dr. 
Mark A. Fogelsong of Eli Lilly and 
Company, Indianapolis, Indiana, 
requests approval to conduct large-scale 
experiments and production involving 
Cephalosporium acremonium strain 
LU4-79-6 under less than Biosafety 
Level 1 — Large Scale (BLl-LS) 
conditions. Information on C. 
acremonium and construction of strain 
LU4-79-6 are provided in the 
submission. 
OMB's “Mandatory Information 
Requirements for Federal Assistance Program 
Announcements" (45 FR 39592) requires a 
statement concerning the official government 
programs contained in the Catalog of Federal 
Domestic Assistance. Normally NIH lists in 
its announcements the number and title of 
affected individual programs for the guidance 
of the public. Because the guidance in this 
notice covers not only virtually every NIH 
program but also essentially every Federal 
research program in which DNA recombinant 
molecule techniques could be used, it has 
been determined to be not cost effective or in 
the public interest to attempt to list these 
programs. Such a list would likely require 
several additional pages. In addition. NIH 
could not be certain that every Federal 
program would be included as many Federal 
agencies, as well as private organizations, 
both national and international, have elected 
to follow the NIH Guidelines. In lieuof the 
individual program listing. NIH invites 
readers to direct questions to the information 
address above about whether individual 
programs listed in the Catalog of Federal 
Domestic Assistance are affected. 
Dated: December 17, 1987. 
James C. Hill, 
Acting Director, National Institute of Allergy 
and Infectious Diseases. 
(FR Doc. 87-29466 Filed 12-22-87; 8:45 am] 
BILLING CODE 4140-01-M 
[ 102 ] 
Recombinant DNA Research, Volume 13 
